1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| TCG Crossover Fund IIIFiled to raise in 2025, with no closing reported yet. | 2025 | $1.2B | $0 | 0 |
| TCG Crossover Fund IIFiled to raise in 2023, with no closing reported yet. | 2023 | $900M | $0 | 0 |
| TCG Crossover Fund I | 2021 | $800M | $800M | 79 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Chen Yu | Quiet | Biotech & pharma, Medical devices | 9 | 0 |
Classified sectors of TCG Crossover’s own portfolio companies, based on 9 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of TCG Crossover’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Tcgx Asia Life Sciences | 9 | ADARx Pharmaceuticals, Arbor Biotechnologies, Kala Pharmaceuticals, LB PHARMACEUTICALS, Nexcida Therapeutics, Nora Therapeutics, Outpost Medicine, SentreHEART, ShouTi |
| Vivo Innovation | 9 | ADARx Pharmaceuticals, Arbor Biotechnologies, Kala Pharmaceuticals, LB PHARMACEUTICALS, Nexcida Therapeutics, Nora Therapeutics, Outpost Medicine, SentreHEART, ShouTi |
| Third Rock Ventures | 2 | Kala Pharmaceuticals, Nora Therapeutics |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Absolute Return | 1 | Arbor Biotechnologies |
| ARCH Venture Partners | 1 | Arbor Biotechnologies |
| Atlas Venture | 1 | Kala Pharmaceuticals |
| Bain Capital Life Sciences | 1 | ADARx Pharmaceuticals |
| Balcera Fund Ltd | 1 | Arbor Biotechnologies |
| Buckeye Fund Ltd | 1 | Arbor Biotechnologies |
| Cadence Alternative Investments | 1 | Arbor Biotechnologies |
| Caduceus Capital | 1 | ADARx Pharmaceuticals |
| Cascade Fund Ltd | 1 | Arbor Biotechnologies |
| Cedar Investments Ltd | 1 | Arbor Biotechnologies |
| Charles2 Fund Ltd | 1 | Arbor Biotechnologies |
| Clear Box Investments Ltd | 1 | Arbor Biotechnologies |
A shared board seat: a company where filings name a TCG Crossover partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
